163293 20251024172259.0 doi 10.1089/mdr.2010.0105 sideral 67746 ART-2011-67746 eng Pardos de la Gándara, M. (orcid)0000-0002-3273-6392 Prevalence and Characterization of Extended-Spectrum Beta-lactamases-Producing Salmonella enterica Isolates in Saragossa, Spain (2001–2008) 2011 We analyzed the prevalence of resistance to extended-spectrum cephalosporins (ESCs) among clinical strains of Salmonella enterica collected by the Laboratory of Clinical Microbiology in the University Clinical Hospital Lozano Blesa in the region of Aragón (Spain), for which very few epidemiological information exists. A total of 2,092 strains of S. enterica were identified in stool samples from patients with gastroenteritis. Five isolates showed an extended-spectrum beta-lactamase (ESBL) phenotype: four isolates of S. enterica serotype Virchow harbored the ESBL-encoding blaCTX-M-9 gene and an isolate of serotype Enteritidis carried a blaCTX-M-1 gene, which, to the best of our knowledge, is described here for the first time in this serotype of S. enterica. The five ESC-resistant isolates were also resistant to spectinomycin, streptomycin, kanamycin, sulfonamides, tetracycline, and trimethoprim as well as to nalidixic acid. The ESBL isolate of serotype Enteritidis, however, remained susceptible to kanamycin and nalidixic acid. A class 1 integron of 1.5 kb was detected for the four serotype Virchow isolates with the gene cassette dfrA16–aadA2. The blaCTX-M-9 gene was carried by an ∼300-kb IncHI2 conjugative plasmid in the case of the S. enterica serotype Virchow isolates. The blaCTX-M-1 gene was carried by an ∼100-kb IncI1-N conjugative plasmid for the serotype Enteritidis ESC-resistant isolate. All the four ESC-resistant strains of S. enterica serotype Virchow clustered together in a XbaI pulsed-field gel electrophoresis, which also revealed a strong similarity between them and some pulsotypes of S. enterica serotype Virchow from France. Access copy available to the general public Unrestricted info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 2.153 2011 INFECTIOUS DISEASES 44 / 70 = 0.629 2011 Q3 T2 PHARMACOLOGY & PHARMACY 130 / 259 = 0.502 2011 Q3 T2 MICROBIOLOGY 65 / 113 = 0.575 2011 Q3 T2 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Seral, C. Universidad de Zaragoza (orcid)0000-0002-9742-1463 Castillo, F.J. Universidad de Zaragoza (orcid)0000-0002-2519-701X Rubio-Calvo M.C. Universidad de Zaragoza (orcid)0000-0002-7068-0983 Weill, F.X. 1008 630 Universidad de Zaragoza Dpto. Microb.Med.Pr.,Sal.Públ. Área Microbiología 17, 2 (2011), 207-213 Microb. drug resist. Microbial Drug Resistance 1076-6294 783199 http://zaguan.unizar.es/record/163293/files/texto_completo.pdf Postprint 967245 http://zaguan.unizar.es/record/163293/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:163293 articulos driver 2025-10-24-16:56:37 ARTICLE